Meeting
2021 ASCO Annual Meeting
Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.
Authors
Muhammad Umair Mushtaq
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
Muhammad Umair Mushtaq , Mary Luder , Moazzam Shahzad , Nausheen Ahmed , Haitham Abdelhakim , Rajat Bansal , Ramesh Balusu , Sibgha Gull Chaudhary , Shaun DeJarnette , Clint Divine , Robert Kribs , Leyla Shune , Anurag K Singh , Sunil H. Abhyankar , Siddhartha Ganguly , Joseph McGuirk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Allogenic Stem Cell Transplantation
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7033)
DOI
10.1200/JCO.2021.39.15_suppl.7033
Abstract #
7033
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Retrospective review of outcomes of patients with multiple myeloma with COVID-19 infection (two-center study).
First Author: Hamid Ehsan
Poster
2022 ASCO Annual Meeting
An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19).
First Author: Dimpy P Shah
Poster
2021 ASCO Annual Meeting
Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).
First Author: Nicholas M. Mark
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop